State of Wyoming Sells 18,159 Shares of Pfizer Inc. $PFE

Key Points

• The State of Wyoming reduced its holdings in Pfizer Inc. by 81.3%, ending the first quarter with only 4,176 shares valued at $106,000 after selling 18,159 shares.
• Pfizer reported strong quarterly earnings of $0.78 EPS, surpassing analysts' expectations, with a revenue of $14.65 billion for the quarter, marking a 10.3% increase year-over-year.
• Institutional investors currently own 68.36% of Pfizer's stock, with multiple firms modifying their positions recently, including Gould Capital LLC which increased its stake by 97.2%.

State of Wyoming lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 81.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,176 shares of the biopharmaceutical company's stock after selling 18,159 shares during the quarter. State of Wyoming's holdings in Pfizer were worth $106,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PFE. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter worth approximately $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth approximately $28,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 1.3%

Pfizer stock traded down $0.33 during mid-day trading on Monday, hitting $24.55. The stock had a trading volume of 49,188,016 shares, compared to its average volume of 34,669,424. The stock has a 50-day simple moving average of $24.85 and a two-hundred day simple moving average of $24.32. The stock has a market capitalization of $139.56 billion, a PE ratio of 13.06, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Jefferies Financial Group increased their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.